Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03655236 · ClinicalTrials.gov registry record · Phase 2
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
A Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 513
- Enrollment target
NCT03655236: Clinical Trial Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT03655236 is a Phase 2 study that was terminated before completion, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 513 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (286% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03655236, a Phase 2 study, was terminated before completion, sponsored by Sun Pharma Advanced Research Company Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 513 participants
- Enrollment target
Study Summary
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for subjects who have completed week 40 of Part 1
Primary Outcome
Part III: Motor examination: 18 items. Score range: 0-132, 32 and below is mild, 59 and above is severe.
Interventions
- OTHER placebo
- DRUG K0706
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2019-02-18 |
| Est. Completion | 2024-06-06 |
| Phase | Phase 2 |
Why NCT03655236 stopped before completion
NCT03655236 is an interventional study that assigns participants to a tested intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (286% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03655236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03655236 about?
NCT03655236 is a clinical study titled "PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706". This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for sub...
What is the current status of trial NCT03655236?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 513 participants. The study started on 2019-02-18. Estimated completion is 2024-06-06.
What interventions are being tested in trial NCT03655236?
The interventions under investigation include: placebo (OTHER), K0706 (DRUG).
Who is sponsoring clinical trial NCT03655236?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03655236's enrollment target sits among peer trials
513 67th of 2000 higher than 1,934 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI